PLN 129
Key Takeaways
Risk factor
Very poor trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable analyst view
Data is available to registered users only
Data is available to registered users only
About
Scope Fluidics S.A. is a biotechnology firm dedicated to conceiving and advancing initiatives that harness microfluidic technologies within medical diagnostics and the broader healthcare landscape. Among its key offerings is BacterOMIC, a specialized system for conducting antibiotic susceptibility testing. This enterprise, established in 2010, conducts its operations from Warsaw, Poland.
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks.
Data is available to registered users only
Target Price
The average target price of SCP.WA is 224 and suggests 73.6% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Data is available to registered users only